» Articles » PMID: 36226869

Is It Necessary for Patients with Potentially Resectable Esophageal Squamous Cell Cancer to Receive Routine Preoperative Brain MRI/CT?

Overview
Journal Thorac Cancer
Date 2022 Oct 13
PMID 36226869
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aimed to investigate the value and efficiency of routine brain MRI or CT in the preoperative workup for patients with potentially resectable (cT N ) thoracic esophageal squamous cell cancer (ESCC).

Methods: This was a prospective cross-sectional clinical trial (ChiCTR1800020304). A total of 385 patients with potentially resectable (cT N ) thoracic ESCC diagnosed from October 2018 to August 2020 were included. Plain brain MRI or CT was performed preoperatively to detect brain metastases (BrM). The primary endpoint was BrM detected by imaging.

Results: Of all 385 patients, the rate of positive brain MRI/CT findings was 1% (n = 4). BrM Patients received chemoradiotherapy, and the median OS was 6 months (95% CI: 4.303-7.697). All 381 remaining patients with initial negative brain MRI/CT diagnosis revealed no brain-associated symptoms within 6 months. The median follow-up for patients without BrM was 20 months (range, from 6 to 32). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of plain MRI or CT to detect BrM were all 100%.

Conclusions: Preoperative plain MRI or CT is an effective method to detect BrM for potentially resectable (cT N ) thoracic ESCC. However, due to the low incidence, the value of brain MRI/CT as a routinely preoperational examination in potentially resectable esophageal squamous cell cancer is rather limited. Therefore, preoperative brain MRI/CT should not be recommended as a routine preoperative examination for ESCC.

Citing Articles

Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT?.

Wei X, Luo P, Chen X, Wang Z, Xu L, Xie H Thorac Cancer. 2022; 13(23):3304-3309.

PMID: 36226869 PMC: 9715792. DOI: 10.1111/1759-7714.14686.

References
1.
Gabrielsen T, Eldevik O, Orringer M, Marshall B . Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. AJNR Am J Neuroradiol. 1995; 16(9):1915-21. PMC: 8338213. View

2.
Schaefer P, Budzik Jr R, Gonzalez R . Imaging of cerebral metastases. Neurosurg Clin N Am. 1996; 7(3):393-423. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Galldiks N, Kocher M, Ceccon G, Werner J, Brunn A, Deckert M . Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro Oncol. 2019; 22(1):17-30. PMC: 6954406. DOI: 10.1093/neuonc/noz147. View

5.
Brant-Zawadzki M, Badami J, Mills C, Norman D, Newton T . Primary intracranial tumor imaging: a comparison of magnetic resonance and CT. Radiology. 1984; 150(2):435-40. DOI: 10.1148/radiology.150.2.6691098. View